Apollo Therapeutics has signed an exclusive license agreement with Sunshine Lake Pharma.APL-18881 (HEC88473) is designed to simultaneously activate FGF21 and GLP-1 receptors, with both pathways showing potential for treating a variety of metabolic diseases. The collaboration between Apollo and Sunshine Lake underscores their shared goal of addressing unmet medical needs in global markets.This partnership is for the development of APL-18881 (HEC88473), a promising bi-specific fusion protein targeting FGF21 and GLP-1 receptors.

阿波罗治疗公司（Apollo Therapeutics）与阳光湖制药公司（Sunshine Lake Pharma）签署了独家许可协议。APL-18881（HEC88473）旨在同时激活FGF21和GLP-1受体，这两种途径均显示出治疗多种代谢疾病的潜力。阿波罗和阳光湖之间的合作强调了他们共同的目标，即解决全球市场未满足的医疗需求。这种伙伴关系是为了开发APL-18881（HEC88473），这是一种靶向FGF21和GLP-1受体的有前途的双特异性融合蛋白。

These receptors are well-established in clinical research, with several monoclonal agonists in late-stage development or already approved for various conditions.Under the terms of the agreement, Sunshine Lake will retain the rights for the development, manufacturing, and commercialization of APL-18881 in China.

这些受体在临床研究中已经确立，几种单克隆激动剂处于晚期开发阶段或已被批准用于各种条件。根据协议条款，阳光湖将保留APL-18881在中国的开发、制造和商业化权利。

Apollo, meanwhile, will manage these rights in all other global markets. Sunshine Lake will receive an upfront payment of $12 million, with the potential to earn up to $926 million in development, regulatory, and commercial milestone payments. These milestones are tied to specific sales targets in major markets, in addition to tiered royalties based on net sales, ranging from high single to low double digits.This collaboration marks an important step for both companies.

与此同时，阿波罗将在所有其他全球市场管理这些权利。阳光湖将收到1200万美元的预付款，有可能在开发、监管和商业里程碑付款中获得9.26亿美元。这些里程碑与主要市场的具体销售目标有关，此外，还根据净销售额（从高单位数到低双位数）支付分层版税。这一合作标志着两家公司迈出了重要的一步。

For Apollo, APL-18881 will be its fifth program in clinical development, complementing its expanding portfolio of novel drug candidates. Apollo’s strategy includes not only discovering new treatments in partnership with academic institutions but also acquiring and licensing promising clinical-stage assets that align with its expertise in genetics, discovery science, and preclinical research.APL-18881 is currently undergoing Phase 2 clinical trials for type 2 diabetes in China.

对于阿波罗来说，APL-18881将是其临床开发的第五个项目，补充其不断扩大的候选新药组合。阿波罗的战略不仅包括与学术机构合作发现新的治疗方法，还包括收购和许可有前途的临床阶段资产，这些资产与其在遗传学、发现科学和临床前研究方面的专业知识相一致。APL-18881目前正在中国进行2型糖尿病的2期临床试验。